← 返回

癌症免疫疗法的进展

英文原题:Advances in cancer immunotherapies.

查看英文原题

Advances in cancer immunotherapies.

PubMed 2023/04/13(内容时间) Cell Q1 · IF 45.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

利用免疫系统识别和消除癌症的治疗方式,即癌症免疫治疗,已成为癌症治疗的一个独特支柱。其中最有前景的治疗方法包括治疗性疫苗、免疫检查点阻断、双特异性T细胞衔接器(BiTEs)和过继细胞疗法。这些方法具有共同的作用机制,即引发针对肿瘤抗原的基于T细胞的免疫反应,无论是内源性还是工程化的,但固有免疫系统,特别是抗原呈递细胞,与免疫效应细胞之间的相互作用也是癌症免疫治疗疗效的基础,并且利用这些细胞的方法也正在开发中。要查看此SnapShot,请打开或下载PDF。

展开英文摘要原文

Therapeutic modalities that engage the immune system to recognize and eliminate cancer, known as cancer immunotherapy, has emerged as a distinct pillar of cancer therapy. Among the most promising treatment approaches are therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs) and adoptive cell therapies.

These approaches share a common mechanism of action, which is elicitation of a T-cell-based immune response, either endogenous or engineered, against tumor antigens, but interactions between the innate immune system, particularly antigen-presenting cells, and immune effectors also underlie the efficacy of cancer immunotherapies and approaches engaging these cells are also under development. To view this SnapShot, open or download the PDF.

论文信息

作者
Dagher OK、Schwab RD、Brookens SK、Posey AD Jr
第一作者单位
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.United States
通讯作者单位
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA.United States
期刊
Cell2023 Apr 13
原文标识
PubMed 37059073 · DOI 10.1016/j.cell.2023.02.039